| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2001;103:1191.)
© 2001 American Heart Association, Inc.
Brief Rapid Communications |
Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia
From the Center for Cardiovascular Disease Prevention (P.M.R., N.R.), Brigham and Women’s Hospital, Boston, Mass; the Department of Clinical Pathology, Children’s Hospital Medical Center (N.R.), Boston, Mass; and Bayer Pharmaceuticals, Westhaven, Conn (S.P.L.).
Correspondence to Dr Paul Ridker, Brigham and Women’s Hospital, 900 Commonwealth Avenue East, Boston, MA 02115. E-mail pridker{at}partners.org
Background—Long-term therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) has been shown to reduce levels of C-reactive protein (CRP). However, the generalizability, speed of onset, and dose-response characteristics of this effect are uncertain.
Methods and Results—We measured CRP, LDL cholesterol (LDL-C), and HDL cholesterol (HDL-C) levels among 785 patients with primary hypercholesterolemia at baseline and after 8 weeks of therapy with either 0.4 or 0.8 mg of cerivastatin. Overall, cerivastatin resulted in a 13.3% reduction in median CRP levels (P<0.001) and a 24.5% reduction in mean CRP levels (P<0.001). Although LDL-C promptly decreased in a dose-dependent manner (mean LDL-C reduction, 37.3% for 0.4 mg and 42.2% for 0.8 mg of cerivastatin), no clear dose-response effect of cerivastatin on CRP was observed, nor was there any substantive correlation between the magnitude of change in CRP and the magnitude of change in LDL-C (r=-0.08) or the magnitude of change in HDL-C (r=-0.04). Thus, <2% of the variance in the percent change in CRP over 8 weeks could be attributed to the percent change in either of these lipid parameters. Further, there was no evidence of correlation between baseline CRP levels and baseline lipid levels or between end-of-study CRP levels and end-of-study lipid levels.
Conclusions—Among 785 patients with primary hypercholesterolemia, CRP levels were significantly reduced within 8 weeks of initiating cerivastatin therapy in a lipid-independent manner.
Key Words: statins • inflammation • C-reactive protein • cholesterol
This article has been cited by other articles:
 |
|
 |
|
  T. Y. Tang, S. P.S. Howarth, S. R. Miller, M. J. Graves, A. J. Patterson, J.-M. U-King-Im, Z. Y. Li, S. R. Walsh, A. P. Brown, P. J. Kirkpatrick, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study: Evaluation Using Ultrasmall Superparamagnetic Iron Oxide-Enhanced Magnetic Resonance Imaging in Carotid Disease J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2039 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B Rafnsson, I. J Deary, and F. Fowkes Peripheral arterial disease and cognitive function Vascular Medicine, February 1, 2009; 14(1): 51 - 61. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Ruckerl, A. Peters, N. Khuseyinova, M. Andreani, W. Koenig, C. Meisinger, K. Dimakopoulou, J. Sunyer, T. Lanki, F. Nyberg, et al. Determinants of the Acute-Phase Protein C-Reactive Protein in Myocardial Infarction Survivors: The Role of Comorbidities and Environmental Factors Clin. Chem., February 1, 2009; 55(2): 322 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease Clin. Chem., February 1, 2009; 55(2): 209 - 215. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Isma, J. Barani, I. Mattiasson, B. Lindblad, and A. Gottsater Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia Angiology, October 1, 2008; 59(5): 542 - 548. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Falk, S. Kadiev, G. J. Criner, S. M. Scharf, O. A. Minai, and P. Diaz Cardiac Disease in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 543 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Sutton, D. R. Crosslin, S. H. Shah, S. C. Nelson, A. Bassil, A. B. Hale, C. Haynes, P. J. Goldschmidt-Clermont, J. M. Vance, D. Seo, et al. Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets Hum. Mol. Genet., May 1, 2008; 17(9): 1318 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Gao, L. Linhartova, A. McD. Johnston, and D. R. Thickett Statins and sepsis Br. J. Anaesth., March 1, 2008; 100(3): 288 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ridker C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk: Moving an Inflammatory Hypothesis Toward Consensus J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2129 - 2138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kinlay Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein: A Meta-Analysis J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2003 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Fagan, H. F. Elewa, and D. J. Rychly Statin Therapy for Secondary Stroke Prevention: Evidence Catches Up to Practice Journal of Pharmacy Practice, April 1, 2007; 20(2): 117 - 122. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Kapiotis, G. Holzer, G. Schaller, M. Haumer, H. Widhalm, D. Weghuber, B. Jilma, G. Roggla, M. Wolzt, K. Widhalm, et al. A Proinflammatory State Is Detectable in Obese Children and Is Accompanied by Functional and Morphological Vascular Changes Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2541 - 2546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Tanaka, Y. Momiyama, R. Ohmori, A. Yonemura, M. Ayaori, M. Ogura, S. Sawada, M. Kusuhara, H. Nakamura, and F. Ohsuzu Effect of atorvastatin on plasma osteopontin levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): e129 - e130. [Full Text] [PDF]
|
|
|
|
 |
|
 P. van der Harst, A. A. Voors, W. H. van Gilst, M. Bohm, and D. J. van Veldhuisen Statins in the treatment of chronic heart failure: Biological and clinical considerations Cardiovasc Res, August 1, 2006; 71(3): 443 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Niu, A. Hozawa, S. Kuriyama, K. Ohmori-Matsuda, T. Shimazu, N. Nakaya, K. Fujita, I. Tsuji, and R. Nagatomi Dietary long-chain n-3 fatty acids of marine origin and serum C-reactive protein concentrations are associated in a population with a diet rich in marine products Am. J. Clinical Nutrition, July 1, 2006; 84(1): 223 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-J. Li, C.-H. Fang, H.-Y. Qian, and W.-L. Hu Time Course of Rapid C-Reactive Protein Reduction by Pravastatin in Patients with Stable Angina Angiology, January 1, 2006; 57(1): 1 - 7. [Abstract] [PDF]
|
|
|
|
|
|
G. S. Ginsburg, M. P. Donahue, and L. K. Newby Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1615 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-J. Li and C.-H. Fang Effects of 4 Weeks of Atorvastatin Administration on the Antiinflammatory Cytokine Interleukin-10 in Patients with Unstable Angina Clin. Chem., September 1, 2005; 51(9): 1735 - 1738. [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Campese, M. K. Nadim, and M. Epstein Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective? J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S11 - S17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tedgui The role of inflammation in atherothrombosis: implications for clinical practice Vascular Medicine, February 1, 2005; 10(1): 45 - 53. [Abstract] [PDF]
|
|
|
|
 |
|
 P. M Ridker, C. P. Cannon, D. Morrow, N. Rifai, L. M. Rose, C. H. McCabe, M. A. Pfeffer, E. Braunwald, and the Pravastatin or Atorvastatin Evaluation and Inf C-Reactive Protein Levels and Outcomes after Statin Therapy N. Engl. J. Med., January 6, 2005; 352(1): 20 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Marz, H. Scharnagl, M. M. Hoffmann, B. O. Boehm, and B. R. Winkelmann The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study) Eur. Heart J., December 1, 2004; 25(23): 2109 - 2119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Spencer, G. C. Fonarow, P. D. Frederick, R. S. Wright, N. Every, R. J. Goldberg, J. M. Gore, W. Dong, R. C. Becker, W. French, et al. Early Withdrawal of Statin Therapy in Patients With Non-ST-Segment Elevation Myocardial Infarction: National Registry of Myocardial Infarction Arch Intern Med, October 25, 2004; 164(19): 2162 - 2168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.D. Waters and K.K. Khush Management of the acute coronary syndrome patient Eur. Heart J. Suppl., July 1, 2004; 6(suppl_C): C49 - C57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Amarenco and A. M. Tonkin Statins for Stroke Prevention: Disappointment and Hope Circulation, June 15, 2004; 109(23_suppl_1): III-44 - III-49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Lindenauer, P. Pekow, K. Wang, B. Gutierrez, and E. M. Benjamin Lipid-Lowering Therapy and In-Hospital Mortality Following Major Noncardiac Surgery JAMA, May 5, 2004; 291(17): 2092 - 2099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Monakier, M. Mates, M. W. Klutstein, J. A. Balkin, B. Rudensky, D. Meerkin, and D. Tzivoni Rofecoxib, a COX-2 Inhibitor, Lowers C-Reactive Protein and Interleukin-6 Levels in Patients With Acute Coronary Syndromes Chest, May 1, 2004; 125(5): 1610 - 1615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Yasmin, C. M. McEniery, S. Wallace, I. S. Mackenzie, J. R. Cockcroft, and I. B. Wilkinson C-Reactive Protein Is Associated With Arterial Stiffness in Apparently Healthy Individuals Arterioscler Thromb Vasc Biol, May 1, 2004; 24(5): 969 - 974. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kumagai, H. Nakashima, and K. Saku The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model Cardiovasc Res, April 1, 2004; 62(1): 105 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. Milani, C. J. Lavie, and M. R. Mehra Reduction in C-reactive protein through cardiac rehabilitation and exercise training J. Am. Coll. Cardiol., March 17, 2004; 43(6): 1056 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L.M. Herrera, T. Didishvili, L. V. Lopez, R. H. Myers, and N. Ruiz-Opazo Genome-Wide Scan Identifies Novel QTLs for Cholesterol and LDL Levels in F2[Dahl RxS]-Intercross Rats Circ. Res., March 5, 2004; 94(4): 446 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Economides, A. Caselli, E. Tiani, L. Khaodhiar, E. S. Horton, and A. Veves The Effects of Atorvastatin on Endothelial Function in Diabetic Patients and Subjects at Risk for Type 2 Diabetes J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 740 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Stauffer, G. L. Hoetzer, D. T. Smith, and C. A. DeSouza Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy J Appl Physiol, January 1, 2004; 96(1): 143 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker and on behalf of the JUPITER Study Group Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial* Circulation, November 11, 2003; 108(19): 2292 - 2297. [Full Text] [PDF]
|
|
|
|
|
|
R. Wolk, P. Berger, R. J. Lennon, E. S. Brilakis, and V. K. Somers Body Mass Index: A Risk Factor for Unstable Angina and Myocardial Infarction in Patients With Angiographically Confirmed Coronary Artery Disease Circulation, November 4, 2003; 108(18): 2206 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.M. Hirschfield and M.B. Pepys C-reactive protein and cardiovascular disease: new insights from an old molecule QJM, November 1, 2003; 96(11): 793 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ferroni, F. Martini, C. M. Cardarello, P. P. Gazzaniga, G. Davi, and S. Basili Enhanced Interleukin-1{beta} in Hypercholesterolemia: Effects of Simvastatin and Low-Dose Aspirin Circulation, October 7, 2003; 108(14): 1673 - 1675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Fukumoto, H. Tsutsui, M. Tsuchihashi, A. Masumoto, A. Takeshita, and Cholesterol Embolism Study(CHEST) Investigators The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study J. Am. Coll. Cardiol., July 16, 2003; 42(2): 211 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. King, A. G. Mainous III, T. A. Buchanan, and W. S. Pearson C-Reactive Protein and Glycemic Control in Adults With Diabetes Diabetes Care, May 1, 2003; 26(5): 1535 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Chan, D. L. Bhatt, D. P. Chew, J. Reginelli, J. P. Schneider, E. J. Topol, and S. G. Ellis Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions Circulation, April 8, 2003; 107(13): 1750 - 1756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Shishehbor, R. J. Aviles, M.-L. Brennan, X. Fu, M. Goormastic, G. L. Pearce, N. Gokce, J. F. Keaney Jr, M. S. Penn, D. L. Sprecher, et al. Association of Nitrotyrosine Levels With Cardiovascular Disease and Modulation by Statin Therapy JAMA, April 2, 2003; 289(13): 1675 - 1680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Blake and P. M. Ridker C-reactive protein and other inflammatory risk markers in acute coronary syndromes J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 37S - 42S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.O Bonetti, L.O Lerman, C Napoli, and A Lerman Statin effects beyond lipid lowering--are they clinically relevant? Eur. Heart J., February 1, 2003; 24(3): 225 - 248. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Zimmerman, C. H. Selzman, C. Cothren, A. C. Sorensen, C. D. Raeburn, and A. H. Harken Diagnostic Implications of C-Reactive Protein Arch Surg, February 1, 2003; 138(2): 220 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Stefanadis, K. Toutouzas, M. Vavuranakis, E. Tsiamis, D. Tousoulis, D.B. Panagiotakos, S. Vaina, C. Pitsavos, and P. Toutouzas Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques Eur. Heart J., November 1, 2002; 23(21): 1664 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.S. Church, C.E. Barlow, C.P. Earnest, J.B. Kampert, E.L. Priest, and S.N. Blair Associations Between Cardiorespiratory Fitness and C-Reactive Protein in Men Arterioscler Thromb Vasc Biol, November 1, 2002; 22(11): 1869 - 1876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Sposito and M. J. Chapman Statin Therapy in Acute Coronary Syndromes: Mechanistic Insight Into Clinical Benefit Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1524 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Plenge, T. L. Hernandez, K. M. Weil, P. Poirier, G. K. Grunwald, S. M. Marcovina, and R. H. Eckel Simvastatin Lowers C-Reactive Protein Within 14 Days: An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction Circulation, September 17, 2002; 106(12): 1447 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tanne, M. Haim, V. Boyko, U. Goldbourt, T. Reshef, S. Matetzky, Y. Adler, Y. A. Mekori, and S. Behar Soluble Intercellular Adhesion Molecule-1 and Risk of Future Ischemic Stroke: A Nested Case-Control Study From the Bezafibrate Infarction Prevention (BIP) Study Cohort Stroke, September 1, 2002; 33(9): 2182 - 2186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Jarvisalo, A. Harmoinen, M. Hakanen, U. Paakkunainen, J. Viikari, J. Hartiala, T. Lehtimaki, O. Simell, and O. T. Raitakari Elevated Serum C-Reactive Protein Levels and Early Arterial Changes in Healthy Children Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1323 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Blake, P. M. Ridker, and K. M. Kuntz Projected life-expectancy gains with statin therapy for individuals with elevated c-reactive protein levels J. Am. Coll. Cardiol., July 3, 2002; 40(1): 49 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt and E. J. Topol Need to Test the Arterial Inflammation Hypothesis Circulation, July 2, 2002; 106(1): 136 - 140. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden European Association for the Study of Diabetes (EASD) 2001 Meeting Diabetes Care, July 1, 2002; 25(7): 1229 - 1236. [Full Text] [PDF]
|
|
|
|
|
|
L. K. Newby, A. Kristinsson, M. V. Bhapkar, P. E. Aylward, A. P. Dimas, W. W. Klein, D. K. McGuire, D. J. Moliterno, F. W. A. Verheugt, W. D. Weaver, et al. Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes JAMA, June 19, 2002; 287(23): 3087 - 3095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Spooner and D. P. Zipes Sudden Death Predictors: An Inflammatory Association Circulation, June 4, 2002; 105(22): 2574 - 2576. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ridker Inflammatory Biomarkers, Statins, and the Risk of Stroke: Cracking a Clinical Conundrum Circulation, June 4, 2002; 105(22): 2583 - 2585. [Full Text] [PDF]
|
|
|
|
|
|
G.J. Blake and P.M. Ridker C-reactive protein and prognosis after percutaneous coronary intervention Eur. Heart J., June 2, 2002; 23(12): 923 - 925. [Full Text] [PDF]
|
|
|
|
|
|
C. Kluft Is C-reactive protein an additional, surrogate end-point for statin treatment? Eur. Heart J., May 2, 2002; 23(10): 761 - 764. [Full Text] [PDF]
|
|
|
|
|
|
W.F. Riesen, H. Engler, M. Risch, W. Korte, and G. Noseda Short-term effects of atorvastatin on C-reactive protein Eur. Heart J., May 2, 2002; 23(10): 794 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Loftus and M. Thompson The role of matrix metalloproteinases in vascular disease Vascular Medicine, May 1, 2002; 7(2): 117 - 133. [Abstract] [PDF]
|
|
|
|
|
|
P. Libby, P. M. Ridker, and A. Maseri Inflammation and Atherosclerosis Circulation, March 5, 2002; 105(9): 1135 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.J. Blake and P.M. Ridker Tumour necrosis factor-{alpha}, inflammatory biomarkers, and atherogenesis Eur. Heart J., March 1, 2002; 23(5): 345 - 347. [Full Text] [PDF]
|
|
|
|
|
|
K. C. B. Tan, W. S. Chow, S. C. F. Tam, V. H. G. Ai, C. H. L. Lam, and K. S. L. Lam Atorvastatin Lowers C-Reactive Protein and Improves Endothelium-Dependent Vasodilation in Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 563 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.M. Ridker Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial Eur. Heart J., December 1, 2001; 22(23): 2135 - 2137. [PDF]
|
|
|
|
|
|
R. Blackburn, P. Giral, E. Bruckert, J.-M. Andre, S. Gonbert, M. Bernard, M. J. Chapman, and G. Turpin Elevated C-Reactive Protein Constitutes an Independent Predictor of Advanced Carotid Plaques in Dyslipidemic Subjects Arterioscler Thromb Vasc Biol, December 1, 2001; 21(12): 1962 - 1968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takemoto and J. K. Liao Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1712 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mann, M. Skeaff, S. Truswell, F. B Hu, F. Sacks, W. C Willett, L. Hooper, C. D Summerbell, R. L Thompson, N. E Capps, et al. Dietary fats and prevention of cardiovascular disease BMJ, October 27, 2001; 323(7319): 1000 - 1000. [Full Text]
|
|
|
|
|
|
G. J. Blake and P. M. Ridker Novel Clinical Markers of Vascular Wall Inflammation Circ. Res., October 26, 2001; 89(9): 763 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Albert, E. Danielson, N. Rifai, P. M Ridker, and for the PRINCE Investigators Effect of Statin Therapy on C-Reactive Protein Levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A Randomized Trial and Cohort Study JAMA, July 4, 2001; 286(1): 64 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ridker, N. Rifai, M. Clearfield, J. R. Downs, S. E. Weis, J. S. Miles, A. M. Gotto Jr., and the Air Force/Texas Coronary Atherosclerosis Preve Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events N. Engl. J. Med., June 28, 2001; 344(26): 1959 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Tracy Is Visceral Adiposity the "Enemy Within"? Arterioscler Thromb Vasc Biol, June 1, 2001; 21(6): 881 - 883. [Full Text] [PDF]
|
|
|
|
|
|
M. K. Chung, D. O. Martin, D. Sprecher, O. Wazni, A. Kanderian, C. A. Carnes, J. A. Bauer, P. J. Tchou, M. J. Niebauer, A. Natale, et al. C-Reactive Protein Elevation in Patients With Atrial Arrhythmias: Inflammatory Mechanisms and Persistence of Atrial Fibrillation Circulation, December 11, 2001; 104(24): 2886 - 2891. [Abstract] [Full Text] [PDF]
|
|